GENFIT (GNFT.PA)
FR0004163111 - Common Stock
We assign a fundamental rating of 5 out of 10 to GNFT. GNFT was compared to 76 industry peers in the Biotechnology industry. Both the profitability and the financial health of GNFT get a neutral evaluation. Nothing too spectacular is happening here. GNFT is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
GNFT had positive earnings in the past year.
GNFT had a negative operating cash flow in the past year.
GNFT had negative earnings in 4 of the past 5 years.
In the past 5 years GNFT reported 4 times negative operating cash flow.
1.2 Ratios
GNFT has a better Return On Assets (11.43%) than 97.18% of its industry peers.
GNFT has a Return On Equity of 22.87%. This is amongst the best in the industry. GNFT outperforms 94.37% of its industry peers.
With an excellent Return On Invested Capital value of 11.07%, GNFT belongs to the best of the industry, outperforming 91.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| ROIC | 11.07% |
ROA(3y)-1.25%
ROA(5y)-15.15%
ROE(3y)-3.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 26.51%, GNFT belongs to the best of the industry, outperforming 95.77% of the companies in the same industry.
Looking at the Operating Margin, with a value of 28.39%, GNFT belongs to the top of the industry, outperforming 91.55% of the companies in the same industry.
GNFT's Gross Margin of 97.41% is amongst the best of the industry. GNFT outperforms 92.96% of its industry peers.
GNFT's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.39% | ||
| PM (TTM) | 26.51% | ||
| GM | 97.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y4.62%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GNFT is creating some value.
The number of shares outstanding for GNFT remains at a similar level compared to 1 year ago.
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
The debt/assets ratio for GNFT is higher compared to a year ago.
2.2 Solvency
GNFT has an Altman-Z score of 0.50. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.50, GNFT is in line with its industry, outperforming 52.11% of the companies in the same industry.
GNFT has a Debt/Equity ratio of 0.61. This is a neutral value indicating GNFT is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.61, GNFT perfoms like the industry average, outperforming 46.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.5 |
ROIC/WACC1.45
WACC7.62%
2.3 Liquidity
GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.74, GNFT is in the better half of the industry, outperforming 69.01% of the companies in the same industry.
A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
GNFT has a better Quick ratio (3.74) than 70.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 153.62% over the past year.
The Revenue has grown by 182.34% in the past year. This is a very strong growth!
The Revenue has been growing by 38.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)153.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.19%
Revenue 1Y (TTM)182.34%
Revenue growth 3Y70.09%
Revenue growth 5Y38.49%
Sales Q2Q%413.61%
3.2 Future
Based on estimates for the next years, GNFT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.99% on average per year.
GNFT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.66% yearly.
EPS Next Y302.86%
EPS Next 2Y-64.03%
EPS Next 3Y18.99%
EPS Next 5YN/A
Revenue Next Year54.53%
Revenue Next 2Y-23.27%
Revenue Next 3Y-11.25%
Revenue Next 5Y27.66%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 14.57, which indicates a correct valuation of GNFT.
GNFT's Price/Earnings ratio is rather cheap when compared to the industry. GNFT is cheaper than 91.55% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 31.71. GNFT is valued rather cheaply when compared to this.
GNFT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.57 | ||
| Fwd PE | N/A |
4.2 Price Multiples
GNFT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GNFT is cheaper than 91.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.65 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of GNFT may justify a higher PE ratio.
A more expensive valuation may be justified as GNFT's earnings are expected to grow with 18.99% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y-64.03%
EPS Next 3Y18.99%
5. Dividend
5.1 Amount
No dividends for GNFT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENFIT
EPA:GNFT (10/21/2024, 5:28:58 PM)
5.39
+0.06 (+1.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap268.75M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.57 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 28.39% | ||
| PM (TTM) | 26.51% | ||
| GM | 97.41% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)153.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y302.86%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)182.34%
Revenue growth 3Y70.09%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y